Regeneron and Sanofi to provide data on Libtayo at ESMO

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) will present a diverse set of data from their joint clinical program investigating Libtayo (cemiplimab-rwlc) at the ESMO 2018 Congress (European Society for Medical Oncology) from October 19 to 23 in Munich, Germany. These data span six different tumor types, including non-small cell lung cancer , cervical cancer, cutaneous squamous cell carcinoma (CSCC), hepatocellular carcinoma (HCC), head and neck squamous cell carcinoma and basal cell carcinoma. Libtayo is a fully-human monoclonal antibody targeting the immune checkpoint receptor PD-1 (programmed cell death protein-1). All six of the abstracts accepted at ESMO focus on ongoing Libtayo clinical trials. Among the joint Regeneron and Sanofi presentations are new clinical data from a Phase 1 expansion cohort investigating Libtayo in combination with radiotherapy in advanced NSCLC as well as longer-term follow-up data from the advanced CSCC expansion cohorts in the Phase 1 trial. Additional abstracts will feature initial data from Phase 1 expansion cohorts investigating Libtayo in cervical cancer, HCC and HNSCC, alongside a trial-in-progress update on the potentially pivotal Phase 2 trial in BCC.
https://thefly.com/landingPageNews.php?id=2801249